SightGlass Vision has introduced “Control the Contrast,” a global professional education campaign aimed at increasing awareness of contrast management as an approach to myopia control. The initiative is centered on the company’s Diffusion Optics Technology (DOT) spectacle lenses, which in studies have demonstrated the ability to slow average myopia progression by up to 75% after 12 months of wear across diverse populations.
DOT spectacle lenses have received FDA Breakthrough Device designation but remain unavailable for US consumers and US-based ECPs cannot prescribe them. In Canada, MiSight spectacle lenses powered by Diffusion Optics Technology are available from CooperVision.
Focus on Contrast Management
As part of the campaign, SightGlass Vision has launched a dedicated website with educational materials. This includes content that explains how contrast in various environments may lead to eye growth and downloadable resources for practitioners.
The campaign comes as childhood myopia continue to rise due to contributing factors such as increased indoor activity and screen use. SightGlass Vision says the campaign is designed to equip providers with information and tools to support earlier intervention.
About DOT Lenses
DOT lenses are designed to mimic natural contrasts by incorporating thousands of elements that softly scatter light before it reaches the retina, thus managing myopia progression.
The company says DOT lenses have been introduced commercially in Canada, China, Israel, Spain, and the United Kingdom and have been worn by more than 1.5 million children to date.
Industry Reaction
“More children are developing myopia at a younger age, making it even more crucial for eye care professionals to be aware of all the options at their disposal for early intervention,” says Andrew Sedgwick, CEO of SightGlass Vision, which was founded in 2016 and operates as a joint venture of CooperVision and Essilor International.
Kylvin Ho, OD, of C U Vision Optometrists in Vancouver, adds that he has seen positive results and reactions from patients after utilizing DOT lenses in his practice. “We’ve seen a high success rate, especially in our younger patients, with many showing slowed progression and stable axial length over time,” he says.